Incentives for R&D for New Antimicrobial Drugs-Reference-Cited by-同舟云学术

Incentives for R&D for New Antimicrobial Drugs

Published:2011-07 Issue:2 Volume:18 Page:331-350
ISSN:1357-1516
Container-title:International Journal of the Economics of Business
language:en
Short-container-title:International Journal of the Economics of Business

Author:

Towse Adrian,Sharma Priya

Publisher

Informa UK Limited

Subject

Economics and Econometrics,Business, Management and Accounting (miscellaneous)

Link

http://www.tandfonline.com/doi/pdf/10.1080/13571516.2011.584434

Reference34 articles.

1. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

2. The Economics of Gene Therapy and of Pharmacogenetics

3. The price of innovation: new estimates of drug development costs

4. ECDC (European Centre for Disease Prevention and Control) and EMEA (European Medicines Agency) (2009)The bacterial challenge: Time to react.Joint technical report (Stockholm: EMEA).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies and Innovations in the Battle Against Antibiotic Resistance;Advances in Medical Diagnosis, Treatment, and Care;2024-03-15

2. Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study;PharmacoEconomics;2023-11-24

3. INVESTING IN INNOVATION: THE RELATIONSHIP BETWEEN R&D SPENDING AND FINANCIAL PERFORMANCE IN THE EUROPEAN PHARMACEUTICAL INDUSTRY;J E EUR CENT ASIAN R;2023

4. Estimating the Clinical and Economic Impact of Introducing a New Antibacterial into Greek Clinical Practice for the Management of Hospital-Acquired Infections with Limited Treatment Options;Infectious Diseases and Therapy;2022-12-21

5. Contemporary challenges in the European pharmaceutical industry: a systematic literature review;Measuring Business Excellence;2022-11-08